Reduced chemotherapy doses and survival in older people with non-small cell lung cancer
Looks back at chemotherapy dosing and survival in older adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
Key facts
- Where
- Hong Kong, Hong KongSee the site
Where in Hong Kong
- Queen Mary Hospital, The University of Hong KongHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Malaya
- Trial code
- NCT07369596
- Record updated
- 2 June 2026
- Original description
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.Read full original descriptionShow less
Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.
This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Inclusion: Age ≥65 years; Histologically confirmed stage IV NSCLC; Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion; Treated with at least ONE cycle of first-line chemotherapy.
Exclusion: Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting; Incomplete survival data.